Status: Recruiting
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Participants needed: 80
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: SoligenixUpdated: Apr 3, 2026Locations: 17
Eligibility criteria
Patients must have a clinical diagnosis of cutaneous T-cell lymphoma (CTCL), Sta... [+3]
History of sun hypersensitivity and photosensitive dermatoses including porphyri... [+13]